Exhibit 10.3
AMENDED AND RESTATED
DEVELOPMENTAL CONSULTING AGREEMENT
This Amended and Restated
Developmental Consulting Agreement (the “Agreement”) is
entered into as of March 31, 2009 (the “Amendment
Date”), by and among Alphatec Spine, Inc., a Delaware
corporation with a principal place of business at 2051 Palomar
Airport Road, Suite 100, Carlsbad, California 92011 (the
“Company”), Stout Medical Group LP, a limited
partnership company organized under the laws of the state of
Delaware, and having a place of business at 410 East Walnut Street,
Suite #8, Perkasie, Pennsylvania 18944 (“Service
Provider”) and for purposes of Sections 3.2, 3.3, 11.14 and
Article 7 hereof only Alphatec Holdings, Inc., a Delaware
corporation with a principal place of business at 2051 Palomar
Airport Road, Suite 100, Carlsbad, California 92008
(“Holdings”). Company and Service Provider are each
hereafter referred to individually as a “Party” and
together as the “Parties”.
WHEREAS, Reference is made to that
certain Developmental Consulting Agreement dated March 3, 2008
(the “Effective Date”) between the parties to this
Amendment (the “Original Agreement”); and
WHEREAS, The Parties desire to amend
and restate the Agreement as set forth herein.
Now, therefore, in consideration of
the mutual promises set forth herein and for other good and
valuable consideration, the receipt and sufficiency of which is
acknowledged by the Parties hereto, the Parties hereto agree that
the Original Agreement is hereby amended and restated in its
entirety as follows:
1.
DEFINITIONS
Whenever used in the Agreement with
an initial capital letter, the terms defined in this Article 1
shall have the meanings specified.
1.1 “Affiliate” shall
mean any company, corporation, partnership, limited liability
company, trust, or other business entity that directly or
indirectly controls, is controlled by, or is under common control
with a designated person or entity, and for such purpose
“control” shall mean the possession, direct or
indirect, of the power to direct or cause the direction of the
management and policies of the entity, whether through the
ownership of voting securities, by contract or
otherwise.
1.2 “Common Stock” shall
mean the common stock of Holdings, and any securities into which
such common stock may hereafter be reclassified, converted or
exchanged.
1.3 “Company
Indemnitees” and “Service Provider Indemnitees”
(each individually an “Indemnitee”) shall have the
meaning given in Article 8.
1.4 “Confidential
Information” shall mean with respect to a Party (the
“Receiving Party”), all information which is disclosed
by the other Party (the “Disclosing Party”) to the
Receiving Party hereunder or to any of its employees, consultants,
Affiliates, licensees or sublicensees, except to the extent that
the Receiving Party can demonstrate by written record or other
suitable physical evidence
1
Portions of this Exhibit were
omitted, as indicated by [***], and have been filed separately with
the Secretary of the Commission pursuant to the Registrant’s
application requesting confidential treatment under Rule 24b-2 of
the Securities Exchange Act of 1934, as amended.
that such information, (a) as of the date
of disclosure is demonstrably known to the Receiving Party or its
Affiliates other than by virtue of a prior confidential disclosure
to such Party or its Affiliates; (b) as of the date of
disclosure is in, or subsequently enters, the public domain,
through no fault or omission of the Receiving Party; (c) is
obtained from a Third Party having a lawful right to make such
disclosure free from any obligation of confidentiality to the
Disclosing Party; or (d) is independently developed by or for
the Receiving Party without reference to or reliance upon any
Confidential Information of the Disclosing Party. Any information
in relation to the subject matter of this Agreement disclosed by a
Party under that certain Mutual Confidentiality Agreement between
the parties dated the 2nd day of July, 2007 shall, subject to the
foregoing exceptions, be considered Confidential Information for
purpose of this Agreement.
1.5 “FDA” shall mean the
United States Food and Drug Administration and any successor agency
or authority thereto.
1.6 “Guarantee and
Agreement” shall mean the guarantee and agreement of Holdings
set forth in Section 11.14 hereof.
1.7 “In-Field Products”
shall have the meaning given in Section 5.3.
1.8 “Joint Inventions”
shall have the meaning given in Section 5.3.
1.9 “License Agreement”
shall mean that certain Amended and Restated License Agreement as
of even date herewith between the Parties relating to
Company’s license of Technology in the Licensed Field from
the Service Provider.
1.10 “Licensed Field”
shall mean: (i) [***]; or (ii) [***].
1.11 “Licensed Product”
shall mean any product sold by Company, its Affiliates or
Sublicensees that embodies or uses any aspect of the Licensed
Patent Rights and/or the Licensed Technology (as such terms are
defined in the License Agreement).
1.12 “Net Sales” shall
mean the gross amount invoiced by or otherwise payable to the
Company, any of its Affiliates or any Sublicensee on account of
sales or other transfers of an In-Field Products anywhere in the
Territory during a designated period less to the extent otherwise
then or previously included in amounts invoiced for such In-Field
Products and in respect of which no previous deduction was
taken):
|
|
1.12.1
|
trade,
cash and quantity discounts or rebates actually allowed or taken on
In-Field Products, including discounts or rebates to governmental
or managed care organizations;
|
2
Portions of this Exhibit were
omitted, as indicated by [***], and have been filed separately with
the Secretary of the Commission pursuant to the Registrant’s
application requesting confidential treatment under Rule 24b-2 of
the Securities Exchange Act of 1934, as amended.
|
|
1.12.2
|
credits or
allowances actually given or made for rejection of, and for
uncollectible amounts (except to the extent later collected) on, or
return of previously sold In-Field Products;
|
|
|
1.12.3
|
any charges for
insurance, freight, and other transportation costs directly related
to the delivery of In-Field Products to the extent included in the
gross invoiced sales price;
|
|
|
1.12.4
|
any tax,
tariff, duty or governmental charge levied on the sales, transfer,
transportation or delivery of an In-Field Products (including any
tax such as a value added or similar tax or government charge),
other than franchise or income tax of any kind whatsoever;
and
|
|
|
1.12.5
|
any import or
export duties or their equivalent borne.
|
“Net Sales” shall not
include amounts invoiced by or otherwise payable to the Company,
any of its Affiliates and/or any Sublicensees for In-Field Products
sold or otherwise transferred to the Company or any of its
Affiliates and/or its Sublicensees, unless the In-Field Products is
consumed by the invoiced entity.
1.13 “Restricted Stock
Agreement” shall have the meaning set forth in
Section 3.2 hereof.
1.14 “Services” shall
have the meaning set forth in Section 2.1 hereof.
1.15 “Shares” shall have
the meaning set forth in Paragraph. 3.4.1(a) hereof.
1.16 “Statement of Work”
shall have the meaning set forth in Section 2.1
hereof.
1.17 “Sublicensee” shall
mean any Third Party to whom Company grants a sublicense of some or
all of the rights granted to Company under this
Agreement.
1.18 “Technology” shall
mean all of the following intangible legal rights, whether or not
filed, perfected, registered or recorded, applicable to the
Licensed Field: (i) inventions, patents, patent disclosures,
patent rights, including any and all continuations,
continuations-in-part, divisionals, reissues, reexaminations,
utility models, industrial designs and design patents or any
extensions thereof, (ii) rights associated with works of
authorship, including without limitation, copyrights, copyright
applications and copyright registrations and (iii) any and all
proprietary ideas, inventions, discoveries, Confidential
Information, data, results, formulae, designs, specifications,
methods, processes, techniques, ideas, know-how, technical
information (including, without limitation, structural and
functional information), process information, pre-clinical
information, clinical information, and any and all proprietary
control and manufacturing data and materials, whether or not
patentable.
1.19 “Term” shall have
the meaning given in Section 9.1.
3
Portions of this Exhibit were
omitted, as indicated by [***], and have been filed separately with
the Secretary of the Commission pursuant to the Registrant’s
application requesting confidential treatment under Rule 24b-2 of
the Securities Exchange Act of 1934, as amended.
1.20 “Territory” shall
mean all countries and jurisdictions of the world.
1.21 “Third Party” shall
mean any person or entity other than Company, Service Provider and
their respective Affiliates.
1.22 “Triggering Event”
shall mean (i) the filing of a 510(k) application with the FDA
(as defined below) with respect to a Licensed Product, or
(ii) the initiation of an Investigational Device Exemption
with the FDA with respect to a Licensed Product.
2. PROFESSIONAL
SERVICES
2.1 Statement of Work . The
Company hereby engages the Service Provider to provide professional
services (the “Services”) set forth on Schedule
A attached hereto (the “Statement of Work”), and
the Service Provider hereby accepts such engagement. The Service
Provider agrees to perform for the Company the Services, and to
provide to the Company the work product set forth in Schedule A
attached hereto. Schedule A may only be amended by mutual
written agreement of the Parties.
2.2 Location and Access .
Except as otherwise stated in the Statement of Work, the Service
Provider shall perform the Services at the Service Provider’s
premises or such other premises that the Company and the Service
Provider may agree in writing.
2.3 Records and Reports . The
Service Provider shall keep accurate written records of its
activities under this Agreement and shall make such records
available to the Company upon request. Unless otherwise stated in
the Statement of Work, the Service Provider shall provide the
Company with periodic written reports on such activities. The
Service Provider shall also provide the Company with such other
reports that the Company may periodically request during the term
of this Agreement.
3. PAYMENTS
3.1 Cash Remuneration To the
Service Provider . The Company shall pay the Service Provider
two-hundred forty thousand dollars ($240,000) in cash in twelve
(12) monthly payments of twenty thousand dollars ($20,000)
each (with the first such first retainer payment due July 30,
2009, and each subsequent retainer payment due thirty
(30) days thereafter) (the “Cash Retainer”);
provided however, that in the event that a Triggering Event occurs
prior to the date that all such monthly payments shall have been
made, all then unpaid amounts of the Cash Retainer shall become due
and payable when scheduled or if earlier within thirty
(30) days of the occurence of the Triggering Event.
3.2 Issuance of Restricted Common
Stock to the Service Provider . The Service Provider and the
Company agree and acknowledge that prior to the Effective Date, the
Company issued to the Service Provider a stock certificate
representing 101,944 shares of restricted Common Stock, represented
by stock certificate number ATEC-00585, dated April 15, 2008
(the “Restricted Common Stock”). The Restricted Common
Stock shall be subject to an Amended and Restated Restricted Stock
Agreement between the parties dated on or about the date hereof
(the “Amended and Restated Restricted Stock
Agreement”).
4
Portions of this Exhibit were
omitted, as indicated by [***], and have been filed separately with
the Secretary of the Commission pursuant to the Registrant’s
application requesting confidential treatment under Rule 24b-2 of
the Securities Exchange Act of 1934, as amended.
3.3 Matters Related to the
Issuance of Common Stock .
|
|
3.3.1
|
Representations, Warranties and Certain
Covenants of the Company. The Company represents, warrants and
covenants that:
|
(a) Assuming the covenant of Service
Provider contained in Subsection 3.3.2 of this Agreement is
complied with, the issuance to Service Provider of each share of
Common Stock (all shares so issued the “Shares”) will
be in compliance with all applicable federal and state securities
laws in connection with the offer, issuance and sale of the
securities.
(b) The execution, delivery and
performance of this Agreement by Holdings, the issuance and sale of
the Shares and the consummation by Holdings of the other
transactions by it contemplated hereby do not and will not on the
date of the issuance and sale of the Shares (i) conflict with
or violate any provision of Holdings’ or any of its
subsidiaries certificates or articles of incorporation, bylaws or
other organizational or charter documents, or (ii) conflict
with, or constitute a default (or an event that with notice or
lapse of time or both would become a default) under, result in the
creation of any lien or encumbrance upon any of the properties or
assets of Holdings or any of its subsidiaries, or give to others
any rights of termination, amendment, acceleration or cancellation
(with or without notice, lapse of time or both) of, any agreement,
credit facility, debt or other instrument or other understanding to
which Holdings or any of its subsidiaries is a party or by which
any property or asset of Holdings or any such subsidiary is bound
or affected, in each case with respect to this Subsection (ii), to
a degree that would have a material adverse effect on the assets or
results of operations of Holdings or its subsidiaries when
considered as a whole (a “Material Adverse Effect”), or
(iii) conflict with or result in a violation of any law, rule,
regulation, order, judgment, injunction, decree or other
restriction of any court or governmental authority to which
Holdings or any such subsidiary is subject (including federal and
state securities laws and regulations), or by which any property or
asset of Holdings or any such subsidiary is bound or affected, in
each case with respect to this Subsection (iii), to a degree that
would have a Material Adverse Effect.
(c) Prior to the issuance of the
Shares, Holdings shall obtain all consents, approvals, orders,
authorizations or registrations, qualifications, designations,
declarations, and make all filings or registrations with any court
or other federal, state, local or other governmental authority or
other person that is required in order to issue the
Shares.
(d) The Shares, when issued in
accordance herewith, will be (i) duly authorized,
(ii) duly and validly issued, (iii) fully paid and
nonassessable, and (iv) free and clear of all liens imposed by
Holdings, other than restrictions on transfer provided for
herein.
5
Portions of this Exhibit were
omitted, as indicated by [***], and have been filed separately with
the Secretary of the Commission pursuant to the Registrant’s
application requesting confidential treatment under Rule 24b-2 of
the Securities Exchange Act of 1934, as amended.
(e) At all times prior to the second
anniversary of the issuance of the Shares during which there are
Shares outstanding which have not been previously (i) sold or
transferred to or through a broker or dealer or underwriter in a
public distribution, or (ii) sold or transferred in a
transaction exempt from the registration and prospectus delivery
requirements of the Securities Act of 1933, as amended (the
“Securities Act”), in the case of either Subsection
(i) or Subsection (ii) in such a manner that, upon the
consummation of such sale or transfer, all transfer restrictions
and restrictive legends with respect to such Shares are removed
upon the consummation of such sale or transfer, Holdings shall use
its commercially reasonable efforts to: (1) comply with the
requirements of Rule 144(c) under the Securities Act with respect
to current public information about Holdings, and (2) furnish
to the Service Provider such non-publicly available reports and
documents of Holdings as Service Provider may reasonably request to
avail itself of Rule 144 of the Securities Act, or any similar rule
or regulation of the United States Securities Exchange Commission
allowing Service Provider to sell the Shares without
registration.
|
|
3.3.2
|
Representations and Warranties of the Service
Provider . The Service
Provider represents and warrants that (i) it is an
“accredited investor” as that term is defined in Rule
501(a) of Regulation D of the Securities Act; (ii) it is
acquiring the Shares for investment for the Service
Provider’s own account and not as a nominee or agent, and not
with a view to the resale or distribution of any part thereof,
without prejudice, however, to Service Provider’s right to at
all times to sell or otherwise dispose of any or all of the Shares
so issued in compliance with applicable federal and state
securities laws and (iii) it does not have any contract,
undertaking, agreement or arrangement with any person to sell,
transfer or grant participation to such person or to any third
person, with respect to any of such Shares.
|
|
|
3.3.3
|
Restrictions
on the Shares . Service
Provider understands and agrees that the Shares may not be sold,
transferred, or otherwise disposed of without registration under
the Securities Act or an exemption therefrom, and that in the
absence of an effective registration statement covering the Shares
or any available exemption from registration under the Securities
Act, the Shares must be held indefinitely. The Service Provider
agrees and acknowledges that the following legend will be placed on
the back of any certificate evidencing the Shares:
|
“THE SECURITIES REPRESENTED
HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED, AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED OR
HYPOTHECATED UNLESS THERE IS AN EFFECTIVE REGISTRATION STATEMENT
UNDER SUCH ACT COVERING SUCH SECURITIES, THE SALE IS MADE IN
ACCORDANCE WITH RULE 144 UNDER THE ACT, OR THE CORPORATION RECEIVES
AN OPINION OF COUNSEL FOR THE HOLDER OF THESE SECURITIES REASONABLY
SATISFACTORY TO THE CORPORATION, STATING THAT SUCH SALE, TRANSFER,
ASSIGNMENT OR HYPOTHECATION IS EXEMPT FROM THE REGISTRATION AND
PROSPECTUS DELIVERY REQUIREMENTS OF SUCH ACT.
6
Portions of this Exhibit were
omitted, as indicated by [***], and have been filed separately with
the Secretary of the Commission pursuant to the Registrant’s
application requesting confidential treatment under Rule 24b-2 of
the Securities Exchange Act of 1934, as amended.
THE SECURITIES REPRESENTED HEREBY
ARE SUBJECT TO RESTRICTIONS SET FORTH IN A RESTRICTED STOCK
AGREEMENT WITH THIS CORPORATION, A COPY OF WHICH AGREEMENT IS
AVAILABLE FOR INSPECTION AT THE OFFICES OF THE CORPORATION OR WILL
BE MADE AVAILABLE UPON REQUEST.”
|
|
3.3.4
|
Limitation
on the Number of Shares Issued . Notwithstanding anything to the contrary in
this Agreement, in no event shall the aggregate number of Shares
issued pursuant to this Agreement be greater than nine and
nine-tenths percent (9.9%) of the number of shares of Common
Stock outstanding on the Effective Date. In the event that an
issuance of Shares pursuant to this Agreement would cause an
aggregate issuance of Shares that is more than nine and nine-tenths
percent (9.9%) of the number of shares of Common Stock
outstanding on the Effective Date, the Company shall make a cash
payment to the Service Provider equal to the difference between
cash value of the Shares that were scheduled to be issued pursuant
to this Agreement, and the value of the Shares that were actually
issued after giving effect to the limitation set forth in this
Section 3.3.4.
|
3.4 Service Provider Expenses
. Company will also pay all out-of-pocket costs incurred by the
Service Provider in connection with the provision of the Services,
including costs of any materials utilized, [***]. Company and
Service Provider shall equally split any travel costs incurred by
Service Provider in connection with any development meetings that
occur in the Carlsbad, CA area; provided that prior to such meeting
the Company and Service Provider shall mutually agree on which
representatives of the Service Provider shall attend such meetings.
Company shall reimburse the Service Provider for all travel costs
incurred at the request of the Company, provided that such travel
is requested by the Company. The foregoing sentence shall
specifically exclude all development meetings in the Carlsbad, CA
area. All reimbursement described in this Section 3.4 will be
invoiced monthly by the Service Provider and invoices and are
payable net 45 days.
3.5 Payments to the Company .
The Service Provider shall refund to Company four-hundred thousand
dollars ($400,000) (the “Company Refund”) that had been
paid to the Service Provider pursuant to the Original Agreement,
with the such Company Refund being due and payable on
April 15, 2009.
7
Portions of this Exhibit were
omitted, as indicated by [***], and have been filed separately with
the Secretary of the Commission pursuant to the Registrant’s
application requesting confidential treatment under Rule 24b-2 of
the Securities Exchange Act of 1934, as amended.
4. PROTECTED INFORMATION
4.1 Confidential Information
. Each Party recognizes that the other Party’s Confidential
Information constitutes highly valuable and proprietary
confidential information. Each Party agrees that during the Term
and for five (5) years thereafter, it will keep confidential,
and will cause its employees, consultants, Affiliates and
sublicensees to keep confidential, all Confidential Information of
the other Party. Neither Party nor any of their respective
employees, consultants, Affiliates or sublicensees shall use
Confidential Information of the other Party for any purpose
whatsoever other than exercising any rights granted to it or
reserved by it hereunder. Without limiting the foregoing, each
Party may disclose information to the extent such disclosure is
reasonably necessary to (a) file, prosecute or defend
litigation in accordance with the provisions of this Agreement or
(b) comply with applicable laws, regulations (including those
of the United States Securities Exchange Commission) or court
orders; provided, however, that if a Party is required to make any
such disclosure of the other Party’s Confidential Information
in connection with any of the foregoing, it will give reasonable
advance notice to the other Party of such disclosure requirement
and will use reasonable efforts to cooperate with such other Party
in efforts to secure confidential treatment of such information
required to be disclosed. Each Party agrees that any Confidential
Information disclosed by a Party under that certain Mutual
Confidentiality Agreement between the Parties dated the 2nd day of
July 2007 shall be protected by the obligations set forth therein
through the date hereof and from and after the date hereof shall be
protected by the obligations as to Confidential Information set
forth herein so as to be continuously protected.
4.2 Limited Disclosure and
Use . Each Party agrees that any disclosure of the other
Party’s Confidential Information to any officer, employee,
consultant or agent of the other Party or any of its Affiliates or
Sublicensees shall be made only if and to the extent necessary to
carry out its rights and responsibilities under this Agreement,
shall be limited to the maximum extent possible consistent with
such rights and responsibilities and shall only be made to the
extent any such persons are bound by written confidentiality
obligations to maintain the confidentiality thereof and not to use
such Confidential Information except as expressly permitted by this
Agreement. Each Party further agrees not to disclose or transfer
the other Party’s Confidential Information to any Third
Parties under any circumstance without the prior written approval
from the other Party (such approval not to be unreasonably
withheld), except as otherwise required by law, and except as
otherwise expressly permitted by this Agreement. Each Party shall
take such action, and shall cause its Affiliates or Sublicensees to
take such action, to preserve the confidentiality of each
other’s Confidential Information as it would customarily take
to preserve the confidentiality of its own Confidential
Information, using, in all such circumstances, not less than
reasonable care. Each Party, upon the request of the other Party,
will return all the Confidential Information disclosed or
transferred to it by the other Party pursuant to this Agreement,
including all copies and extracts of documents and all
manifestations in whatever form, within sixty (60) days of
such request or, if earlier, the termination or expiration of this
Agreement; provided however, that a Party may retain (i) any
Confidential Information of the other Party relating to any license
which expressly survives such termination, and (ii) one
(1) copy of all other Confidential Information in inactive
archives in legal counsel’s files solely for the purpose of
establishing the contents thereof.
8
Portions of this Exhibit were
omitted, as indicated by [***], and have been filed separately with
the Secretary of the Commission pursuant to the Registrant’s
application requesting confidential treatment under Rule 24b-2 of
the Securities Exchange Act of 1934, as amended.
4.3 Publicity . Neither Party
may publicly disclose the existence or terms or any other matter of
fact regarding this Agreement without the prior written consent of
the other Party, which consent shall not be unreasonably withheld
or delayed; provided, however, that either Party may make such a
disclosure (i) to the extent required by law or by the
requirements of any nationally recognized securities exchange,
quotation system or over-the-counter market on which such Party has
its securities listed or traded, or (ii) with respect to
Company, to any prospective Sublicensees, or to investors,
prospective investors, lenders and other potential financing
sources, who are obligated to keep such information confidential.
The Parties, upon the execution of this Agreement, will mutually
agree to a press release with respect to this transaction for
publication. Once such press release or any other written statement
is approved for disclosure by both Parties, neither Party may make
subsequent public disclosure of the contents of such statement
without the further approval of the other Party.
4.4 Use of Name . Neither
Party shall employ or use the name of the other Party in any
promotional materials or advertising without the prior express
written permission of the other Party.
5. OWNERSHIP OF IDEAS,
COPYRIGHTS AND PATENTS
5.1 Company Inventions . All
Technology, whether patentable, copyrightable or not, which is
solely conceived, reduced to practice or developed by the Company,
its employees, agents (it being agreed to by the Parties that the
Service Provider shall not be deemed to be an agent of the Company
with respect to this Section 5.1) or its Affiliates (the
“Company Inventions”) is the sole and exclusive
property of the Company, and the Service Provider shall not exploit
any of the Company Inventions.
5.2 Service Provider
Inventions . All Technology, whether patentable, copyrightable
or not, which is solely conceived, reduced to practice or developed
by the Service Provider, its Affiliates or any of their employees,
agents (it being agreed to by the Parties that the Company shall
not be deemed to be an agent of the Company or any if its
Affiliates with respect to this Section 5.2) is the sole and
exclusive property of the Service Provider. With respect to
Technology described in the preceding sentence which is developed
in the course of performance of the Services (the “Service
Provider Inventions”), the Service Provider hereby grants to
the Company, subject to the terms and conditions of this Agreement,
an exclusive (even as to Service Provider and its Affiliates),
worldwide, license, including the right to grant sublicenses, under
such Service Provider Inventions: (a) to conduct research and
development in support of the licensed uses describe in clause
(b) of this Section, and (b) to make, hav